Mesenchymal stem (stromal) cells (MSCs) are the most common cells used in cell therapy trials. These cells act via a myriad of paracrine pathways that mostly involved releasing extracellular vesicles (EVs). EVs are
vesicles originating from the plasma membrane (ectosomes), multivesicular bodies (exosomes), or apoptotic cells
(apoptotic bodies), and contain proteins, nucleic acids, lipids and metabolites. Cells release EVs under
physiological and non-physiological conditions communicate with other cells.
For the last decade, the therapeutic potential of MSCs -derived EVs (MSC-EVs) has been shown to be promising for many diseases including autoimmune, brain, cancer, eye, gastrointestinal, heart, liver, musculoskeletal, pancreas, nervous system, respiratory system, reproductive system, skin, urinary system, and vascular-related diseases.
Despite the explosive amount of reports on MSC-EVs therapies, still critical and rigorous discussions are required to pave the road toward industrialized MSC-EVs therapeutic applications. Moreover, increasing and compelling evidence revealed the practicality of using MSC-EVs due to the feasibility of large-scale production, storage, and administration of EVs compared to cells. Therefore, MSC-EVs therapy may replace MSC therapy in the future. The goal of this Research Topic, therefore, is to gather new research on the therapeutic applications of MSC-EVs in a variety of diseases, considerations of the use of MSC-EVs as a drug delivery vehicle and address the current challenges associated with large scale production of MSC-EVs.
Submissions to this Research Topic may consider, but are not limited to, the following themes:
• Reports on the therapeutic application of MSC-EVs in different diseases. Specifically, controversial issues are encouraged in this collection, for example, the utilization of MSC-EVs in cancer therapies.
• The use of MSC-EVs as a drug delivery vehicle, including biodistribution of MSC-EVs in animal models and pharmaceutical assessments of drug loading and release.
• Discussion of current considerations and challenges in industrialized production of MSC-EVs.
• Methodological reports on large-scale production of MSC-EVs.
• Comparative studies on different subtypes/subpopulations of MSC-EVs.
Mesenchymal stem (stromal) cells (MSCs) are the most common cells used in cell therapy trials. These cells act via a myriad of paracrine pathways that mostly involved releasing extracellular vesicles (EVs). EVs are
vesicles originating from the plasma membrane (ectosomes), multivesicular bodies (exosomes), or apoptotic cells
(apoptotic bodies), and contain proteins, nucleic acids, lipids and metabolites. Cells release EVs under
physiological and non-physiological conditions communicate with other cells.
For the last decade, the therapeutic potential of MSCs -derived EVs (MSC-EVs) has been shown to be promising for many diseases including autoimmune, brain, cancer, eye, gastrointestinal, heart, liver, musculoskeletal, pancreas, nervous system, respiratory system, reproductive system, skin, urinary system, and vascular-related diseases.
Despite the explosive amount of reports on MSC-EVs therapies, still critical and rigorous discussions are required to pave the road toward industrialized MSC-EVs therapeutic applications. Moreover, increasing and compelling evidence revealed the practicality of using MSC-EVs due to the feasibility of large-scale production, storage, and administration of EVs compared to cells. Therefore, MSC-EVs therapy may replace MSC therapy in the future. The goal of this Research Topic, therefore, is to gather new research on the therapeutic applications of MSC-EVs in a variety of diseases, considerations of the use of MSC-EVs as a drug delivery vehicle and address the current challenges associated with large scale production of MSC-EVs.
Submissions to this Research Topic may consider, but are not limited to, the following themes:
• Reports on the therapeutic application of MSC-EVs in different diseases. Specifically, controversial issues are encouraged in this collection, for example, the utilization of MSC-EVs in cancer therapies.
• The use of MSC-EVs as a drug delivery vehicle, including biodistribution of MSC-EVs in animal models and pharmaceutical assessments of drug loading and release.
• Discussion of current considerations and challenges in industrialized production of MSC-EVs.
• Methodological reports on large-scale production of MSC-EVs.
• Comparative studies on different subtypes/subpopulations of MSC-EVs.
